3 Anti-Retroviral and Ingredients Leader, Excipients and Food Additive Maker and US Generics Exporter Stocks With a Strong Future Roadmap: Laurus Labs, Sudeep Pharma and Alembic Pharmaceuticals
- October 26, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Laurus Labs, Sudeep Pharma and Alembic Pharmaceuticals: ROE of 11.9% to 19.6% and FY22 to FY26 revenue CAGR of 8.4% to 17.6%. Prices as of 23 Oct 2026.
Quick Answer
The three API, excipient and generic pharma stocks to watch are Laurus Labs, Sudeep Pharma and Alembic Pharmaceuticals. Their return on equity ranges from 11.9% to 19.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 17.6%. Sudeep Pharma leads on both return on equity at 19.6% and revenue growth at 17.6% a year. Prices are based on the 23 October 2026 close, and this article is educational, not investment advice.
API, excipient and generic pharma stocks offer a focused view of a sector where demand keeps widening. Laurus Labs, Sudeep Pharma and Alembic Pharmaceuticals cover an anti-retroviral and ingredients leader, an excipients and food additive maker and a US generics exporter.
This list covers three API, excipient and generic pharma stocks with complete current figures: Laurus Labs, Sudeep Pharma and Alembic Pharmaceuticals. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are API, Excipient and Generic Pharma Stocks?
API, excipient and generic pharma stocks are listed companies that make active ingredients, excipients and finished generics for drug makers and patients. Their earnings depend on global orders, product approvals, capacity use and input costs.
API, Excipient and Generic Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Laurus Labs | 1,970 | 111,434 | 102.2 | 36.0 | 16.8 | 0.48 |
| Sudeep Pharma | 966.2 | 11,352 | 61.8 | 35.1 | 19.6 | 0.17 |
| Alembic Pharmaceuticals | 760.1 | 14,914 | 21.6 | 35.7 | 11.9 | 0.25 |
On valuation, Alembic Pharmaceuticals trades at a P/E below the industry P/E, while Laurus Labs and Sudeep Pharma trade above it, which reflects the growth the market already expects. Readers comparing API, excipient and generic pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do API, Excipient and Generic Pharma Stocks Have a Strong Roadmap in India?
API, excipient and generic pharma stocks have a strong roadmap in India because global drug makers want dependable suppliers outside a single region, and Indian firms are adding capacity in ingredients, excipients and finished medicines.
- Supply diversification. Global buyers add Indian ingredient suppliers.
- Niche inputs. Excipients and additives are essential to every formulation.
- US generics. Approved plants keep new launches coming.
Why Laurus Labs Features Among These API, Excipient and Generic Pharma Stocks
Among the API, excipient and generic pharma stocks on this list, Laurus Labs is a Hyderabad-based pharmaceutical company with businesses in active ingredients, finished formulations, custom synthesis and biotechnology, with a leading position in anti-retroviral medicines.
Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%.
In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0.
Roadmap: The company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.
What to watch: Follow the ramp-up of new capacity in formulations and the order flow in custom synthesis.
Why Sudeep Pharma Features Among These API, Excipient and Generic Pharma Stocks
Among the anti-retroviral and ingredient shares on this list, Sudeep Pharma makes pharmaceutical excipients, food ingredients and nutritional additives such as minerals and fortification products for domestic and global customers.
In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%.
Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1.
Roadmap: Excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.
What to watch: Check capacity expansion progress and export revenue growth.
Why Alembic Pharmaceuticals Features Among These API, Excipient and Generic Pharma Stocks
Among the three companies on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.
The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7.
Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore.
Roadmap: The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.
What to watch: Follow new approvals in the United States, the pace of complex generic launches and domestic growth.
Laurus Labs vs Sudeep Pharma vs Alembic Pharmaceuticals on Key Financials
The table below sets the three API, excipient and generic pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Laurus Labs | 4,951 | 6,868 | 8.5% | 890 | 13.0% |
| Sudeep Pharma | 350 | 671 | 17.6% | 174 | 26.0% |
| Alembic Pharmaceuticals | 5,356 | 7,399 | 8.4% | 671 | 9.1% |
Sudeep Pharma posts the highest return on equity in this group at 19.6%. Alembic Pharmaceuticals has the largest FY26 revenue at Rs 7,399 crore, and Sudeep Pharma shows the fastest revenue growth with a 17.6% compound annual rate. A useful habit with API, excipient and generic pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Laurus Labs | 1,580 | 2,035 | 28.8% |
| Sudeep Pharma | 130 | 164 | 25.9% |
| Alembic Pharmaceuticals | 1,717 | 2,165 | 26.1% |
Key Risks to Check Before Investing in API, Excipient and Generic Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these API, excipient and generic pharma stocks, the main points are: Long-term anti-retroviral and ingredient shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory checks. Plant inspections can affect approvals.
- Price pressure. Generic prices abroad can fall.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter API, excipient and generic pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on API, Excipient and Generic Pharma Stocks
API, excipient and generic pharma stocks reward patient research into demand, execution and financial strength. Laurus Labs, Sudeep Pharma and Alembic Pharmaceuticals each have a clear plan to widen their reach. Based on the 23 October 2026 close, Laurus Labs trades at Rs 1,970, Sudeep Pharma at Rs 966.2 and Alembic Pharmaceuticals at Rs 760.1. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these API, excipient and generic pharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track API, excipient and generic pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are API, excipient and generic pharma stocks?
Ans. API, excipient and generic pharma stocks are listed companies that make active ingredients, excipients and finished generics for drug makers and patients. Their earnings depend on global orders, product approvals, capacity use and input costs. This list looks at three of them, Laurus Labs, Sudeep Pharma and Alembic Pharmaceuticals, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.
Which API, excipient and generic pharma stocks are covered in this list?
Ans. This list covers Laurus Labs, Sudeep Pharma and Alembic Pharmaceuticals. Based on the 23 October 2026 close, Laurus Labs traded at Rs 1,970, Sudeep Pharma at Rs 966.2 and Alembic Pharmaceuticals at Rs 760.1. Their return on equity ranges from 11.9% to 19.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 17.6%.
Why do API, excipient and generic pharma stocks have a strong future roadmap in India?
Ans. API, excipient and generic pharma stocks have a strong roadmap in India because global drug makers want dependable suppliers outside a single region, and Indian firms are adding capacity in ingredients, excipients and finished medicines. The main drivers are as follows. Supply diversification. Global buyers add Indian ingredient suppliers. Niche inputs. Excipients and additives are essential to every formulation. US generics. Approved plants keep new launches coming. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Laurus Labs performed financially?
Ans. Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0. Looking ahead, the company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.
How has Sudeep Pharma performed financially?
Ans. Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1. Looking ahead, excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.
How has Alembic Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.
What risks should investors check before buying API, excipient and generic pharma stocks?
Ans. Investors should check a few risks before buying API, excipient and generic pharma stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices abroad can fall. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of API, excipient and generic pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
